Women taking control when medicine left them with few options
For generations, women's health was shaped by research that largely excluded them — a quiet institutional neglect that left gaps in treatment, understanding, and care. FemTech has emerged as both a correction and a reimagining: a multi-billion dollar field that began with period-tracking apps and has grown into a broad movement addressing reproductive health, racial equity, chronic disease, and the structural barriers that have long defined women's medical experience. Fueled by regulatory shifts, telehealth expansion, and international investment, the field now stands at a threshold where technology may begin to dismantle the very systems it was built to work around.
- Decades of gender bias in medical research left women with incomplete diagnoses, misaligned treatment guidelines, and a healthcare system that was never fully designed for them.
- The 2022 overturning of Roe v. Wade accelerated demand for alternative care pathways, pushing FemTech from a niche sector into an urgent, politically charged necessity.
- Platforms like Health in Her HUE are going beyond biological tracking to confront racial and economic disparities, signaling that FemTech's ambitions are now explicitly systemic.
- Qatar Science & Technology Park and Merck have launched dedicated accelerator programs, injecting international capital and institutional legitimacy into the sector's growth.
- The industry's next frontier — cardiovascular disease, cancer, and chronic conditions long understudied in women — could redefine not just tools, but the entire architecture of women's healthcare.
A decade ago, FemTech meant little more than a period-tracking app. Today it is a multi-billion dollar industry, and its ambitions have grown to match the scale of the problem it was born to address.
The field emerged from a clear-eyed recognition that women's healthcare had been systematically shortchanged. Medical research historically favored male subjects, treatment guidelines were built on incomplete data, and funding for women's health lagged. FemTech began as a workaround — a way for women to reclaim health information the traditional system had failed to provide. What started as fertility and menstrual tools has since expanded into a broad ecosystem that explicitly accounts for racial disparities and economic barriers, with platforms like Invocares and Health in Her HUE leading that charge.
Several forces converged to accelerate this growth. Shifting cultural attitudes, the regulatory upheaval following the 2022 overturning of Roe v. Wade, and the mainstreaming of telehealth all created new demand. International institutions took notice: Qatar Science & Technology Park and Merck launched accelerator programs specifically to fund FemTech innovation, lending the sector both capital and credibility.
The most consequential shift, however, is still unfolding. FemTech is now moving beyond reproductive health toward conditions long understudied in women — cardiovascular disease, cancer, chronic illness — areas where the research gap has had life-or-death consequences. The promise here is not merely a new set of tools, but a structural reimagining: healthcare systems designed from the ground up around what women actually need, rather than adapted from frameworks that were never built with them in mind.
A decade ago, the technology aimed at women's health was narrow and specific: an app to track your period, maybe a tool to understand your fertility window. Today, FemTech—the umbrella term for female-focused health care technology—has become something far larger and more ambitious. It is now a multi-billion dollar industry, and it is reshaping how women access medical care across a much wider landscape than anyone might have predicted.
The field emerged from a straightforward observation: women's health care had been systematically neglected. Medical research had long favored male subjects. Treatment guidelines were built on incomplete data. Funding for women's health initiatives lagged behind other areas. These gaps were not accidental—they reflected what researchers call deep-rooted gender biases embedded in how medicine itself was practiced and studied. FemTech began as a response to that disparity, a way for women to take control of their own health information when the traditional medical system had left them with few options.
What started small has expanded rapidly. Early apps for menstrual tracking and fertility awareness have given way to a much broader ecosystem of tools and services. Some platforms, like Invocares and Health in Her HUE, do more than track biological data—they explicitly address women's health inequity within larger systems, accounting for racial disparities and economic barriers that shape health outcomes. The field has grown because conditions aligned to make growth possible. Attitudes toward women's health have shifted. Regulatory upheaval—most notably the 2022 overturning of Roe v. Wade in the United States—created both urgency and demand. Telehealth became accessible to millions. International funding bodies recognized an opportunity: Qatar Science & Technology Park and Merck launched collaborative accelerator programs specifically designed to fund FemTech innovation.
But the real transformation is just beginning. The next phase of FemTech will move beyond reproductive health entirely. Researchers and entrepreneurs are now turning their attention to conditions that have long been understudied in women: cardiovascular disease, cancer, and various chronic illnesses that affect women differently than men, or that have been poorly understood because women were excluded from the research that might have illuminated them. These are not niche concerns. They are among the leading causes of illness and death.
What makes this shift significant is not just that new tools are being built, but that they are being built with intention—backed by sustained investment, supported by policy changes, and designed with access in mind. The promise is not merely technological. It is structural. If these innovations succeed, they could begin to dismantle the pathways through which women have traditionally accessed care, replacing them with systems designed from the ground up to address what women actually need. That is a different kind of medicine than what came before.
Citas Notables
FemTech emerged as a response to longstanding disparities in women's health care, with major gaps in research funding and medical treatment stemming from deep-rooted gender biases— Jenny Castillo Cato, JMIR Correspondent
These innovations create opportunities to address longstanding gender disparities and redefine how women access and experience medical care outside of traditional pathways— Jenny Castillo Cato, JMIR Correspondent
La Conversación del Hearth Otra perspectiva de la historia
Why did it take so long for technology companies to focus on women's health?
Because medicine itself had already decided women's health wasn't a priority. If the research wasn't being done, if the data wasn't being collected, then there was no obvious market for tools to help women manage conditions that nobody was studying.
So FemTech is filling a gap that the medical establishment created?
Exactly. It's not that women suddenly needed better tools. It's that the traditional system had failed them so completely that entrepreneurs saw an opening—and women were desperate enough to use it.
The article mentions racial and economic disparities. How does FemTech address those?
Some platforms are trying to, explicitly. But technology alone can't fix systemic inequality. A tracking app doesn't change the fact that a Black woman might face discrimination in a doctor's office, or that a low-income woman can't afford the care the app recommends.
So what's the real value of FemTech, then?
Information and agency. If you understand your own body better, if you have data to bring to a doctor, if you can access care remotely when local options are limited—that shifts the power dynamic, at least a little.
And now it's moving into cardiovascular disease and cancer. Why those areas?
Because they kill women, and we barely understand how they present in women's bodies. We've been treating them based on research done mostly on men. FemTech is saying: let's study women, let's build tools around what we actually find.